Sequent Scientific Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: June 13, 2025, 5:35 am

Market Cap	4,871 Cr.
Current Price	195
High / Low	241/111
Stock P/E	220
Book Value	28.1
Dividend Yield	0.00 %
ROCE	8.97 %
ROE	3.25 %
Face Value	2.00
PEG Ratio	-6.36

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Sequent Scientific Ltd

Competitors of Sequent Scientific Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	142 Cr.	101	247/84.3	27.6	41.7	0.00 %	12.9 %	9.75 %	10.0
MPS Pharmaa Ltd	5.27 Cr.	2.76	4.33/2.50		0.57	0.00 %	9.79 %	59.0 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	41.6 Cr.	56.0	94.9/44.5		8.73	0.00 %	41.5 %	14.4 %	10.0
Gujarat Inject (Kerala) Ltd	32.1 Cr.	21.9	29.1/13.1	31.4	6.83	0.00 %	13.5 %	11.0 %	10.0
Industry Average	18,996.79 Cr	1,191.53		92.43	194.72	0.30%	16.67%	15.20%	6.18

All Competitor Stocks of Sequent Scientific Ltd

Quarterly Result

Metric	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	384	341	338	375	367	333	346	329	361	390	369	391	402
Expenses	350	339	335	365	370	341	331	307	329	348	330	356	355
Operating Profit	33	2	3	10	-3	-8	15	22	32	42	39	34	46
OPM %	9%	1%	1%	3%	-1%	-2%	4%	7%	9%	11%	11%	9%	12%
Other Income	4	-2	1	3	-60	-23	10	7	-1	3	0	6	1
Interest	6	7	8	10	11	10	13	13	12	16	14	15	15
Depreciation	13	14	13	14	15	14	15	15	16	16	17	17	16
Profit before tax	18	-21	-18	-10	-89	-56	-3	1	3	12	8	8	16
Tax %	45%	-27%	-75%	-4%	4%	-38%	123%	-617%	52%	24%	20%	20%	36%
Net Profit	10	-15	-4	-10	-92	-35	-7	11	1	9	6	6	10
EPS in Rs	0.36	-0.60	-0.15	-0.36	-3.75	-1.40	-0.34	0.33	-0.04	0.26	0.10	0.14	0.37

Last Updated: May 31, 2025, 7:51 am

Below is a detailed analysis of the quarterly data for Sequent Scientific Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Sales, as of Mar 2025, the value is 402.00 Cr.. The value appears strong and on an upward trend. It has increased from 391.00 Cr. (Dec 2024) to 402.00 Cr., marking an increase of 11.00 Cr..
For Expenses, as of Mar 2025, the value is 355.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 356.00 Cr. (Dec 2024) to 355.00 Cr., marking a decrease of 1.00 Cr..
For Operating Profit, as of Mar 2025, the value is 46.00 Cr.. The value appears strong and on an upward trend. It has increased from 34.00 Cr. (Dec 2024) to 46.00 Cr., marking an increase of 12.00 Cr..
For OPM %, as of Mar 2025, the value is 12.00%. The value appears strong and on an upward trend. It has increased from 9.00% (Dec 2024) to 12.00%, marking an increase of 3.00%.
For Other Income, as of Mar 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6.00 Cr. (Dec 2024) to 1.00 Cr., marking a decrease of 5.00 Cr..
For Interest, as of Mar 2025, the value is 15.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 15.00 Cr..
For Depreciation, as of Mar 2025, the value is 16.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 17.00 Cr. (Dec 2024) to 16.00 Cr., marking a decrease of 1.00 Cr..
For Profit before tax, as of Mar 2025, the value is 16.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Dec 2024) to 16.00 Cr., marking an increase of 8.00 Cr..
For Tax %, as of Mar 2025, the value is 36.00%. The value appears to be increasing, which may not be favorable. It has increased from 20.00% (Dec 2024) to 36.00%, marking an increase of 16.00%.
For Net Profit, as of Mar 2025, the value is 10.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Dec 2024) to 10.00 Cr., marking an increase of 4.00 Cr..
For EPS in Rs, as of Mar 2025, the value is 0.37. The value appears strong and on an upward trend. It has increased from 0.14 (Dec 2024) to 0.37, marking an increase of 0.23.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 2:55 pm

Metric	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	327	395	443	606	684	848	1,039	1,179	1,362	1,413	1,421	1,370	1,511
Expenses	340	389	425	550	641	765	914	1,009	1,150	1,303	1,409	1,308	1,363
Operating Profit	-13	6	18	56	43	83	125	170	212	109	12	61	148
OPM %	-4%	2%	4%	9%	6%	10%	12%	14%	16%	8%	1%	4%	10%
Other Income	3	-54	48	14	9	436	9	10	-0	11	-58	-6	8
Interest	33	34	43	38	28	33	33	36	24	16	36	48	58
Depreciation	29	29	32	46	40	41	42	51	51	52	56	62	67
Profit before tax	-73	-110	-8	-14	-17	444	59	94	137	53	-138	-55	31
Tax %	-11%	1%	40%	19%	-3%	3%	3%	13%	24%	15%	-11%	-46%
Net Profit	-65	-110	-12	-16	-16	431	57	82	104	45	-122	-30	23
EPS in Rs	-5.39	-8.09	-0.70	-0.78	-0.57	17.30	1.97	2.81	3.84	1.65	-4.86	-1.44	0.46
Dividend Payout %	0%	0%	0%	0%	0%	1%	10%	0%	13%	0%	0%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	-69.23%	89.09%	-33.33%	0.00%	2793.75%	-86.77%	43.86%	26.83%	-56.73%	-371.11%	75.41%
Change in YoY Net Profit Growth (%)	0.00%	158.32%	-122.42%	33.33%	2793.75%	-2880.52%	130.63%	-17.03%	-83.56%	-314.38%	446.52%

Sequent Scientific Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	13%
5 Years:	6%
3 Years:	3%
TTM:	13%

Compounded Profit Growth
10 Years:	46%
5 Years:	-20%
3 Years:	-18%
TTM:	206%

Stock Price CAGR
10 Years:	5%
5 Years:	18%
3 Years:	25%
1 Year:	60%

Return on Equity
10 Years:	8%
5 Years:	2%
3 Years:	-3%
Last Year:	3%

Last Updated: Unknown

Balance Sheet

Last Updated: June 12, 2025, 2:45 pm

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	27	30	48	49	49	49	50	50	50	50	50	50
Reserves	30	61	898	928	599	657	637	678	642	649	607	654
Borrowings	418	473	312	416	305	325	343	277	365	444	488	481
Other Liabilities	148	343	265	503	380	346	424	381	378	374	389	416
Total Liabilities	623	908	1,523	1,896	1,332	1,378	1,454	1,386	1,435	1,517	1,534	1,602
Fixed Assets	238	474	586	684	476	498	577	536	564	605	592	587
CWIP	43	39	24	33	18	23	13	31	12	55	16	15
Investments	0	59	428	428	239	180	171	83	38	0	4	0
Other Assets	342	336	485	751	599	677	693	737	821	856	922	1,000
Total Assets	623	908	1,523	1,896	1,332	1,378	1,454	1,386	1,435	1,517	1,534	1,602

Below is a detailed analysis of the balance sheet data for Sequent Scientific Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Equity Capital, as of Mar 2025, the value is 50.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 50.00 Cr..
For Reserves, as of Mar 2025, the value is 654.00 Cr.. The value appears strong and on an upward trend. It has increased from 607.00 Cr. (Mar 2024) to 654.00 Cr., marking an increase of 47.00 Cr..
For Borrowings, as of Mar 2025, the value is 481.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 488.00 Cr. (Mar 2024) to 481.00 Cr., marking a decrease of 7.00 Cr..
For Other Liabilities, as of Mar 2025, the value is 416.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 389.00 Cr. (Mar 2024) to 416.00 Cr., marking an increase of 27.00 Cr..
For Total Liabilities, as of Mar 2025, the value is 1,602.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,534.00 Cr. (Mar 2024) to 1,602.00 Cr., marking an increase of 68.00 Cr..
For Fixed Assets, as of Mar 2025, the value is 587.00 Cr.. The value appears to be declining and may need further review. It has decreased from 592.00 Cr. (Mar 2024) to 587.00 Cr., marking a decrease of 5.00 Cr..
For CWIP, as of Mar 2025, the value is 15.00 Cr.. The value appears to be declining and may need further review. It has decreased from 16.00 Cr. (Mar 2024) to 15.00 Cr., marking a decrease of 1.00 Cr..
For Investments, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 4.00 Cr..
For Other Assets, as of Mar 2025, the value is 1,000.00 Cr.. The value appears strong and on an upward trend. It has increased from 922.00 Cr. (Mar 2024) to 1,000.00 Cr., marking an increase of 78.00 Cr..
For Total Assets, as of Mar 2025, the value is 1,602.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,534.00 Cr. (Mar 2024) to 1,602.00 Cr., marking an increase of 68.00 Cr..

Notably, the Reserves (654.00 Cr.) exceed the Borrowings (481.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity +	-45	-24	-0	-7	45	116	115	115	31	17	31	83
Cash from Investing Activity +	-81	-157	-310	-116	7	-68	-72	10	-94	-65	-6	-25
Cash from Financing Activity +	146	179	309	147	-57	-20	-43	-139	67	32	-1	-61
Net Cash Flow	20	-1	-2	24	-5	28	0	-14	4	-16	23	-2

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	-13.00	-412.00	-455.00	-256.00	-373.00	-222.00	-200.00	-173.00	-65.00	-256.00	-432.00	-427.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	73	77	95	116	136	111	98	99	93	85	88	89
Inventory Days	173	175	153	164	165	125	134	132	139	160	152	166
Days Payable	306	198	147	175	208	127	141	133	119	119	107	125
Cash Conversion Cycle	-59	54	101	105	93	110	92	98	112	126	132	131
Working Capital Days	5	47	57	99	79	86	77	74	88	106	112	114
ROCE %	-10%	-4%	9%	2%	1%	40%	9%	12%	16%	6%	-3%	0%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	53.02%	52.79%	52.79%	52.79%	52.79%	52.79%	52.79%	52.79%	52.79%	52.78%	52.76%	52.61%
FIIs	5.84%	6.45%	6.57%	6.25%	5.89%	6.27%	6.03%	6.12%	6.16%	5.69%	6.45%	6.10%
DIIs	2.04%	2.27%	2.79%	2.81%	2.92%	2.92%	3.23%	7.23%	7.59%	8.06%	9.99%	12.01%
Public	38.60%	38.10%	37.48%	37.76%	38.00%	37.64%	37.57%	33.69%	33.29%	33.30%	30.63%	29.12%
Others	0.51%	0.39%	0.39%	0.39%	0.39%	0.39%	0.39%	0.17%	0.17%	0.17%	0.17%	0.16%
No. of Shareholders	1,91,092	1,97,176	1,93,954	1,96,231	1,91,875	1,87,474	1,84,521	1,72,853	1,66,593	1,63,693	1,54,603	1,62,574

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Quant Small Cap Fund	10,788,925	0.94	122.72	10,788,925	2025-04-22 17:25:21	0%
UTI Healthcare Fund	620,305	0.81	7.06	620,305	2025-04-22 03:03:37	0%
Motilal Oswal Nifty Microcap 250 Index Fund	132,097	0.24	1.5	132,097	2025-04-22 03:03:37	0%
ITI Pharma and Healthcare Fund	115,796	0.92	1.32	115,796	2025-04-22 03:03:37	0%
Motilal Oswal S&P BSE Healthcare ETF	1,244	0.15	0.01	1,244	2025-04-22 17:25:21	0%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	2.00	2.00	2.00	2.00	2.00
Basic EPS (Rs.)	-1.44	-4.88	1.67	3.87	2.87
Diluted EPS (Rs.)	-1.44	-4.88	1.65	3.85	2.85
Cash EPS (Rs.)	1.28	-2.66	3.87	6.24	5.34
Book Value[Excl.RevalReserv]/Share (Rs.)	28.58	30.04	29.44	31.26	31.71
Book Value[Incl.RevalReserv]/Share (Rs.)	28.58	30.04	29.44	31.26	31.71
Revenue From Operations / Share (Rs.)	54.91	56.97	56.88	54.82	47.48
PBDIT / Share (Rs.)	2.90	0.73	4.84	8.88	7.26
PBIT / Share (Rs.)	0.43	-1.50	2.78	6.84	5.23
PBT / Share (Rs.)	-2.19	-5.52	2.15	5.50	3.79
Net Profit / Share (Rs.)	-1.19	-4.89	1.81	4.21	3.30
NP After MI And SOA / Share (Rs.)	-1.44	-4.86	1.66	3.84	2.81
PBDIT Margin (%)	5.28	1.29	8.51	16.18	15.29
PBIT Margin (%)	0.79	-2.62	4.89	12.47	11.00
PBT Margin (%)	-3.98	-9.68	3.77	10.03	7.97
Net Profit Margin (%)	-2.16	-8.58	3.18	7.67	6.95
NP After MI And SOA Margin (%)	-2.61	-8.52	2.91	7.00	5.92
Return on Networth / Equity (%)	-5.46	-17.33	6.03	13.11	9.41
Return on Capital Employeed (%)	1.18	-3.72	7.44	18.22	12.37
Return On Assets (%)	-2.32	-7.92	2.86	6.85	4.60
Long Term Debt / Equity (X)	0.21	0.26	0.17	0.12	0.20
Total Debt / Equity (X)	0.68	0.56	0.46	0.27	0.38
Asset Turnover Ratio (%)	0.89	0.17	0.17	0.20	0.19
Current Ratio (X)	1.31	1.50	1.54	1.55	1.50
Quick Ratio (X)	0.76	0.84	0.85	0.97	1.03
Inventory Turnover Ratio (X)	1.77	0.57	0.74	0.87	0.93
Interest Coverage Ratio (X)	1.50	0.51	7.62	9.04	5.05
Interest Coverage Ratio (Post Tax) (X)	0.74	-0.61	3.86	5.65	3.30
Enterprise Value (Cr.)	3313.78	2217.18	3626.83	6172.31	2183.16
EV / Net Operating Revenue (X)	2.42	1.56	2.57	4.53	1.85
EV / EBITDA (X)	45.79	120.86	30.16	28.00	12.10
MarketCap / Net Operating Revenue (X)	2.10	1.27	2.35	4.39	1.64
Price / BV (X)	4.38	2.59	4.86	8.22	2.60
Price / Net Operating Revenue (X)	2.10	1.27	2.35	4.39	1.64
EarningsYield	-0.01	-0.06	0.01	0.01	0.03

After reviewing the key financial ratios for Sequent Scientific Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 2.00.
For Basic EPS (Rs.), as of Mar 24, the value is -1.44. This value is below the healthy minimum of 5. It has increased from -4.88 (Mar 23) to -1.44, marking an increase of 3.44.
For Diluted EPS (Rs.), as of Mar 24, the value is -1.44. This value is below the healthy minimum of 5. It has increased from -4.88 (Mar 23) to -1.44, marking an increase of 3.44.
For Cash EPS (Rs.), as of Mar 24, the value is 1.28. This value is below the healthy minimum of 3. It has increased from -2.66 (Mar 23) to 1.28, marking an increase of 3.94.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 28.58. It has decreased from 30.04 (Mar 23) to 28.58, marking a decrease of 1.46.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 28.58. It has decreased from 30.04 (Mar 23) to 28.58, marking a decrease of 1.46.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 54.91. It has decreased from 56.97 (Mar 23) to 54.91, marking a decrease of 2.06.
For PBDIT / Share (Rs.), as of Mar 24, the value is 2.90. This value is within the healthy range. It has increased from 0.73 (Mar 23) to 2.90, marking an increase of 2.17.
For PBIT / Share (Rs.), as of Mar 24, the value is 0.43. This value is within the healthy range. It has increased from -1.50 (Mar 23) to 0.43, marking an increase of 1.93.
For PBT / Share (Rs.), as of Mar 24, the value is -2.19. This value is below the healthy minimum of 0. It has increased from -5.52 (Mar 23) to -2.19, marking an increase of 3.33.
For Net Profit / Share (Rs.), as of Mar 24, the value is -1.19. This value is below the healthy minimum of 2. It has increased from -4.89 (Mar 23) to -1.19, marking an increase of 3.70.
For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is -1.44. This value is below the healthy minimum of 2. It has increased from -4.86 (Mar 23) to -1.44, marking an increase of 3.42.
For PBDIT Margin (%), as of Mar 24, the value is 5.28. This value is below the healthy minimum of 10. It has increased from 1.29 (Mar 23) to 5.28, marking an increase of 3.99.
For PBIT Margin (%), as of Mar 24, the value is 0.79. This value is below the healthy minimum of 10. It has increased from -2.62 (Mar 23) to 0.79, marking an increase of 3.41.
For PBT Margin (%), as of Mar 24, the value is -3.98. This value is below the healthy minimum of 10. It has increased from -9.68 (Mar 23) to -3.98, marking an increase of 5.70.
For Net Profit Margin (%), as of Mar 24, the value is -2.16. This value is below the healthy minimum of 5. It has increased from -8.58 (Mar 23) to -2.16, marking an increase of 6.42.
For NP After MI And SOA Margin (%), as of Mar 24, the value is -2.61. This value is below the healthy minimum of 8. It has increased from -8.52 (Mar 23) to -2.61, marking an increase of 5.91.
For Return on Networth / Equity (%), as of Mar 24, the value is -5.46. This value is below the healthy minimum of 15. It has increased from -17.33 (Mar 23) to -5.46, marking an increase of 11.87.
For Return on Capital Employeed (%), as of Mar 24, the value is 1.18. This value is below the healthy minimum of 10. It has increased from -3.72 (Mar 23) to 1.18, marking an increase of 4.90.
For Return On Assets (%), as of Mar 24, the value is -2.32. This value is below the healthy minimum of 5. It has increased from -7.92 (Mar 23) to -2.32, marking an increase of 5.60.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.21. This value is within the healthy range. It has decreased from 0.26 (Mar 23) to 0.21, marking a decrease of 0.05.
For Total Debt / Equity (X), as of Mar 24, the value is 0.68. This value is within the healthy range. It has increased from 0.56 (Mar 23) to 0.68, marking an increase of 0.12.
For Asset Turnover Ratio (%), as of Mar 24, the value is 0.89. It has increased from 0.17 (Mar 23) to 0.89, marking an increase of 0.72.
For Current Ratio (X), as of Mar 24, the value is 1.31. This value is below the healthy minimum of 1.5. It has decreased from 1.50 (Mar 23) to 1.31, marking a decrease of 0.19.
For Quick Ratio (X), as of Mar 24, the value is 0.76. This value is below the healthy minimum of 1. It has decreased from 0.84 (Mar 23) to 0.76, marking a decrease of 0.08.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.77. This value is below the healthy minimum of 4. It has increased from 0.57 (Mar 23) to 1.77, marking an increase of 1.20.
For Interest Coverage Ratio (X), as of Mar 24, the value is 1.50. This value is below the healthy minimum of 3. It has increased from 0.51 (Mar 23) to 1.50, marking an increase of 0.99.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 0.74. This value is below the healthy minimum of 3. It has increased from -0.61 (Mar 23) to 0.74, marking an increase of 1.35.
For Enterprise Value (Cr.), as of Mar 24, the value is 3,313.78. It has increased from 2,217.18 (Mar 23) to 3,313.78, marking an increase of 1,096.60.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 2.42. This value is within the healthy range. It has increased from 1.56 (Mar 23) to 2.42, marking an increase of 0.86.
For EV / EBITDA (X), as of Mar 24, the value is 45.79. This value exceeds the healthy maximum of 15. It has decreased from 120.86 (Mar 23) to 45.79, marking a decrease of 75.07.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 2.10. This value is within the healthy range. It has increased from 1.27 (Mar 23) to 2.10, marking an increase of 0.83.
For Price / BV (X), as of Mar 24, the value is 4.38. This value exceeds the healthy maximum of 3. It has increased from 2.59 (Mar 23) to 4.38, marking an increase of 1.79.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 2.10. This value is within the healthy range. It has increased from 1.27 (Mar 23) to 2.10, marking an increase of 0.83.
For EarningsYield, as of Mar 24, the value is -0.01. This value is below the healthy minimum of 5. It has increased from -0.06 (Mar 23) to -0.01, marking an increase of 0.05.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Sequent Scientific Ltd as of June 13, 2025 is: 163.95

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of June 13, 2025, Sequent Scientific Ltd is Overvalued by 15.92% compared to the current share price 195.00

Intrinsic Value of Sequent Scientific Ltd as of June 13, 2025 is: 107.25

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of June 13, 2025, Sequent Scientific Ltd is Overvalued by 45.00% compared to the current share price 195.00

Last 5 Year EPS CAGR: -34.58%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The company has higher reserves (586.67 cr) compared to borrowings (387.25 cr), indicating strong financial stability. The company has shown consistent growth in sales (254.62 cr) and profit (31.00 cr) over the years.	The stock has a low average ROCE of 6.50%, which may not be favorable. The stock has a high average Working Capital Days of 78.67, which may not be favorable. The stock has a high average Cash Conversion Cycle of 91.25, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sequent Scientific Ltd:
1. Net Profit Margin: -2.16%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 1.18% (Industry Average ROCE: 16.67%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: -5.46% (Industry Average ROE: 15.2%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 0.74
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 0.76
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 220 (Industry average Stock P/E: 92.43)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.68
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Sequent Scientific Ltd. is a Public Limited Listed company incorporated on 28/06/1985 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L99999MH1985PLC036685 and registration number is 036685. Currently Company is involved in the business activities of Manufacture of veterinary preparations. Company's Total Operating Revenue is Rs. 178.26 Cr. and Equity Capital is Rs. 50.06 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	301, 3rd Floor, �Dosti Pinnacle�, Plot No. E7, Road No.22, Mumbai Maharashtra 400604	investorrelations@sequent.in http://www.sequent.in

Management
Name	Position Held
Dr. Kamal K Sharma	Chairman & Ind.Director
Mr. Rajaram Narayanan	Managing Director & CEO
Mr. Sharat Narasapur	Joint Managing Director
Mr. Gregory Andrews	Non Executive Director
Mr. Neeraj Bharadwaj	Non Executive Director
Dr. Fabian Kausche	Non Executive Director
Dr. Hari Babu Bodepudi	Non Executive Director
Mr. Milind Sarwate	Independent Director
Dr.(Mrs.) Kausalya Santhanam	Independent Director

FAQ

What is the intrinsic value of Sequent Scientific Ltd?

Sequent Scientific Ltd's intrinsic value (as of 13 June 2025) is ₹163.95 — 15.92% lower the current market price of 195.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 4,871 Cr. market cap, FY2025-2026 high/low of ₹241/111, reserves of 654 Cr, and liabilities of 1,602 Cr.

What is the Market Cap of Sequent Scientific Ltd?

The Market Cap of Sequent Scientific Ltd is 4,871 Cr..

What is the current Stock Price of Sequent Scientific Ltd as on 13 June 2025?

The current stock price of Sequent Scientific Ltd as on 13 June 2025 is 195.

What is the High / Low of Sequent Scientific Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Sequent Scientific Ltd stocks is ₹241/111.

What is the Stock P/E of Sequent Scientific Ltd?

The Stock P/E of Sequent Scientific Ltd is 220.

What is the Book Value of Sequent Scientific Ltd?

The Book Value of Sequent Scientific Ltd is 28.1.

What is the Dividend Yield of Sequent Scientific Ltd?

The Dividend Yield of Sequent Scientific Ltd is 0.00 %.

What is the ROCE of Sequent Scientific Ltd?

The ROCE of Sequent Scientific Ltd is 8.97 %.

What is the ROE of Sequent Scientific Ltd?

The ROE of Sequent Scientific Ltd is 3.25 %.

What is the Face Value of Sequent Scientific Ltd?

The Face Value of Sequent Scientific Ltd is 2.00.